• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

CSL Share Price Spikes Higher on US$2.1 Billion Profit (ASX:CSL)

Like 0

By Ryan Clarkson-Ledward, Wednesday, 19 August 2020

It seems even a pandemic can’t put a dampener on CSL Ltd’s [ASX:CSL] performance. The biotech superstar has defied all the odds today. Reporting a US$2.1 billion profit for the 2020 financial year. Up 17% from the year prior...

It seems even a pandemic can’t put a dampener on CSL Ltd’s [ASX:CSL] performance.

The biotech superstar has defied all the odds today. Reporting a US$2.1 billion profit for the 2020 financial year. Up 17% from the year prior.

A standout result for a standout company. One that has seen the CSL share price climb 7.34% higher at time of writing. Pushing the stock to levels not seen since late April…

So, is the worst over for this ASX juggernaut?

Yet another year of impressive growth

Once again, leading the charge for CSL was their key immunoglobulin portfolio. With sales for the year up 22%; clocking in at US$4.01 billion.

That figure represents just under half (44%) of CSL’s total US$9.15 billion worth of revenue. An incredible reminder of just how dominant the company is in the sector.

However, that’s not to say they’re lacking when it comes to sales diversity either.

A 21% increase in seasonal flu vaccine sales proves that CSL isn’t a one-trick pony. Proving that the Seqirus arm of the business — which was formed just five years ago — is already a smash hit. Meeting and exceeding all expectations to date.

All of which has helped CSL continue to grow and expand. Making it not only one the largest healthcare companies in Australia, but the world.

Things are certainly looking going well for this iconic business.

But that doesn’t mean there aren’t potential challenges ahead of them…

As CSL’s CEO, Paul Perreault, comments:

‘The COVID-19 pandemic does, however, present a challenge for the global plasma industry. The collection of plasma has been adversely impacted in the past few months as communities respond to shelter-in-place orders, extended lockdowns and other government actions.

‘To mitigate this, we have a number of initiatives in place to sustain plasma collections. It is our view that, at some point, the pandemic will recede and, with that in mind, we continue to invest in plasma collection and manufacturing facilities as well as our hallmark research and development programs.’

In other words, if this pandemic isn’t dealt with soon then CSL could face some headwinds. Because without plasma, their key immunoglobulin market will be adversely affected.

And that is a serious risk that even CSL must be wary of.

Overpriced blue chip, or opportune growth story?

At the end of the day, deciphering CSL’s prospects is tricky.

While they certainly have a strong track record and impressive profitability, they aren’t exactly cheap. With a P/E ratio of 46.2, investors are paying a hefty price for this stock.

Which, if the growth continues, may in hindsight look like a bargain.

But, if the worst comes to bear, well then CSL could have a very dramatic fall from grace.

It is up to shareholders to decide if they’re priced at fair value or not. Considering the fact that the biggest risk right now (the pandemic) is still looking like it’s far from over.

Suffice to say, I personally wouldn’t be putting any money into this stock right now. Not when there are far more promising growth stocks out there.

Take our latest report on ‘high-value small-caps’, for example. Showcasing four stocks that have exponential potential and far more room for upside.

Read all about these opportunities, including four example stocks, right here.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • America on a War Footing: Implications as US Mineral Strategy Turns to Africa
    By James Cooper

    Geologist James Cooper examines the potential implications of America’s heavy focus on West Africa. Why is the US becoming deeply involved here? And what could the consequences be?

  • The biggest quarter on record for this share
    By Callum Newman

    We can see why the stock market didn’t react much to the RBA holding rates steady last meeting. Everyone expects rates to go down. It’s just a question of when. Fixed rate loans, and refinancings, are withering away as the market positions for more rate cuts. This is what you and I want to see as investors…

  • The US$2 Trillion Stablecoin Tsunami
    By Charlie Ormond

    These developments could transform the US$250 billion stablecoin market into a US$2 trillion juggernaut within years.

Primary Sidebar

Latest Articles

  • America on a War Footing: Implications as US Mineral Strategy Turns to Africa
  • The biggest quarter on record for this share
  • The US$2 Trillion Stablecoin Tsunami
  • Trump Sparks Rare Earth Rally
  • Copper Breaks Out: Are You Positioned?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988